Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
Public ClinicalTrials.gov record NCT04645953. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome
Study identification
- NCT ID
- NCT04645953
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Alexza Pharmaceuticals, Inc.
- Other
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Interventions
- 1mg AZ010 Combination Product
- 3mg AZ-010 Combination Product
- Staccato Placebo Combination Product
Combination Product
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 4, 2021
- Primary completion
- Jul 25, 2022
- Completion
- Jul 25, 2022
- Last update posted
- Jun 10, 2025
2021 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Om Research | Lancaster | California | 93535 | — |
| Axis Clinical Trials | Los Angeles | California | 90036 | — |
| Precision Research Institute, LLC | San Diego | California | 92114 | — |
| University of South Florida | Tampa | Florida | 33606 | — |
| Summit Clinical Studies | Athens | Georgia | 30607 | — |
| Infinite Clinical Trials | Morrow | Georgia | 30260 | — |
| Kansas University Medical Center | Kansas City | Kansas | 66160 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| NY Scientific | Brooklyn | New York | 11235 | — |
| Temple University Hospital | Philadelphia | Pennsylvania | 19140 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| New Phase Research & Development, LLC | Knoxville | Tennessee | 37909 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Pioneer Research Solutions | Houston | Texas | 77099 | — |
| Sante Clinical Research | Kerrville | Texas | 78028 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04645953, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2025 · Synced May 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04645953 live on ClinicalTrials.gov.